CROI 2017 Program and Information

Program and Agenda

965 BRIEF BEHAVIORAL INTERVENTION INCREASES PREP DRUG LEVELS IN A REAL-WORLD SETTING Sarit A. Golub 1 , Stephanie Pena 2 , Amy Hilley 3 , John Pachankis 4 , Asa Radix 2 1 City Univ of New York, New York, NY, USA, 2 Callen-Lorde Community Hlth Cntr, New York, NY, USA, 3 Hunter HIV/AIDS Rsr Team, New York, NY, USA, 4 Yale Univ, New Haven, CT, USA

Symposium S-1 VISIONS OF HIV CURE Room 6 E

4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the mechanisms of HIV persistence during antiretroviral therapy and the novel strategies developed to cure HIV infection or at least reduce the size of the viral reservoir. Level of Knowledge: It is assumed that the participants are familiar with the concept of viral reservoirs, HIV latency and cure strategies. Objectives: At the completion of the session, participants will be able to: • Describe the methods used to identify and quantify persistently infected cells during antiretroviral therapy • Evaluate the potential of novel curative strategies • Describe the mechanism by which an immune intervention (vaccine, immune checkpoint blockers) may reduce the size of the viral reservoir Conveners R. Brad Jones , George Washington Univ, Washington, DC, USA Sharon Lewin , Univ of Melbourne, Melbourne, Australia 46 VISUALIZING PERSISTENT HIV IN CLINICAL 4:00 SAMPLES Daniel E. Kaufmann , Univ of Montreal, Montreal, QC, Canada

47 CHARACTERIZING HIV EXPRESSION INVIVO Mary F. Kearney , NCI, NIH, Frederick, MD, USA 4:30

Oral Sessions • Tuesday 5:00

48 IMMUNE-BASED INTERVENTIONS TARGETING INFLAMMATION ANDVIRAL PERSISTENCE Mirko Paiardini , Emory Univ Sch of Med, Atlanta, GA, USA 49 THERAPEUTIC VACCINATION FOR HIV/SIV:WHAT WILL IT TAKE FOR CURE? Louis J. Picker , Oregon Hlth & Sci Univ, Beaverton, OR, USA 5:30

CROI 2017 42